Physician profile
Robert T Thomas
NPI 1134339799
$2,067.32
in general payments reported to CMS, 2019-2025
28 companies · $407 in 2025
The $407 reported for 2025 was more than what a typical Pain Medicine (Physical Medicine & Rehabilitation) provider received nationally (typical 2025 total: $400).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $608 · 2020: $486 · 2021: $155 · 2022: $53.07 · 2023: $123 · 2024: $235 · 2025: $407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $765.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $764.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $462.47 | 2019-2025 | |
| Abbvie INC. | $337.72 | 2022-2025 | Botox |
| Abbott Laboratories | $137.65 | 2019-2023 | Proclaim |
| Mdd US Operations, LLC | $115.87 | 2019 | |
| Pfizer INC. | $112.58 | 2019-2021 | |
| Assertio Therapeutics, INC. | $107.19 | 2019-2020 | |
| Amgen INC. | $90.19 | 2019-2021 | |
| Collegium Pharmaceutical, INC. | $80.23 | 2019-2021 | |
| Zyla Life Sciences, INC. | $63.01 | 2019-2020 | |
| Medtronic Vascular, INC. | $62.79 | 2020 | |
| Biotronik Nro, INC. | $57.58 | 2025 | Prospera |
| Indivior INC. | $44.63 | 2019-2024 | Sublocade |
| Vertex Pharmaceuticals Incorporated | $43.42 | 2025 | |
| Novartis Pharmaceuticals Corporation | $34.99 | 2019 | |
| Redhill Biopharma INC. | $31.54 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spinal Simplicity, LLC | $30.62 | 2025 | Ha Minuteman G3-R |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.75 | 2025 | Relistor |
| Iovance Biotherapeutics, INC. | $25.77 | 2025 | Amtagvi |
| Averitas Pharma INC. | $25.39 | 2024 | Qutenza |
| Almatica Pharma LLC | $24.43 | 2023 | Gralise |
| Lundbeck LLC | $22.29 | 2023 | Vyepti |
| Pacira Therapeutics, INC. | $21.78 | 2019 | |
| Medtronic, INC. | $21.33 | 2025 | Synchromedii |
| Ibsa Pharma INC. | $19.04 | 2023 | Tirosint, Licart |
| Takeda Pharmaceuticals U.S.A., INC. | $18.39 | 2020 | |
| Allergan, INC. | $17.37 | 2020 | |
| Biodelivery Sciences International, INC. | $14.87 | 2020 | |
| Genentech USA, INC. | $14.43 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.